Shots:
- Health Canada has granted a NOC based on the P-II ZUMA-2 trial that evaluates Tecartus in 74 adult patients with r/r MCL who had previously received anthracycline or bendamustine containing CT, an anti-CD20 Ab therapy & BTK inhibitor
- The results demonstrated an ORR of 91%; patients achieving a CR (65%) as assessed by an independent radiologic review committee following a single infusion of Tecartus
- Tecartus is the 1st CAR T therapy to treat a patient with MCL after two or more lines of systemic therapy including BTK inhibitor. Additionally, kite becomes the first company with multiple authorized cell therapies in Canada
Click here to read full press release/ article | Ref: Newswire.Ca | Image: Glassdoor
The post Kite’s Tecartus (brexucabtagene autoleucel) Receives Health Canada’s Approval for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma first appeared on PharmaShots.
